Merck   4Q Revenues: $10.1 billion (-1%) 4Q Earnings: $1.2 billion (+21%) FY Revenues: $39.8 billion (+1%) FY Earnings: $5.7 billion (+28%) Comments: KEYTRUDA sales were up 148% to $1.4 billion for the year driven by new indications and new markets. JANUVIA/JANUMET sales were $6.1 billion, up 2% for the year. ZETIA/VYTORIN sales were down 2% to $3.7 billion. GARDASIL/GARDASIL 9 sales were up 14% to $2.2 billion due to increased pricing and demand in the U.S. PROQUAD, M-M-R II and V...